Navigation Links
Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
Date:11/25/2008

PRINCETON, N.J., Nov. 25 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York and the 2008 Mid-Atlantic Capital Conference in Philadelphia. Mr. Jackson will provide a corporate overview and an update on the company's clinical development programs. The presentations will be held as follows:

    Piper Jaffray Health Care Conference
    Tuesday, December 2, 2008 at 3:50pm ET at the New York Palace Hotel

    Mid-Atlantic Capital Conference
    Wednesday, December 3, 2008 at 2:44pm ET in the Life Science Room of the Pennsylvania Convention Center

About Celator

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on identifying a fixed, synergistic ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery vehicle and maintaining the ratio in patients. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
2. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
3. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
4. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
5. Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... (PRWEB) April 21, 2015 Staying true ... to craft a digital product that makes the world ... with Global Biological Standards Institute (GBSI) to redesign their ... clean, and most importantly, strategy-based. , "Biomedical research is ... - much less to promote it in a narrative ...
(Date:4/21/2015)... , April 21, 2015 ... and development, custom automation, and contract manufacturing, and  ... accessible flow cytometry and cell sorting technology for ... develop a novel flow cytometry platform. ... NanoCellect Biomedical has developed a microchip-based cell sorting ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading ... of Josh Forsythe as VP of Marketing. Mr. ... witnessed a significant expansion in its commercial operations over the ... " Josh Forsythe is a tremendous addition ... MD MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing ...
(Date:4/21/2015)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that it will release ... on Tuesday, April 28, 2015. United Therapeutics ... 2015, at 9:00 a.m. Eastern Time.  The teleconference is ... A rebroadcast of the teleconference will be available for ...
Breaking Biology Technology:Visceral Tells GBSI’s Story Within 30 Seconds of Attention 2Visceral Tells GBSI’s Story Within 30 Seconds of Attention 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... 18 Danaher Corporation (NYSE: DHR ) announced today ... indirect wholly owned subsidiary, to acquire all of the issued and ... pence per share implying an aggregate price of approximately GBP 50 ... The offer enjoys the recommendation of the Board of Genetix who ...
... , Toronto Stock Exchange Symbol: ... (TSX: MS) today provided the following update on corporate developments: ... -----------------, , The Company has completed its substantive review of ... drug candidate for the treatment of multiple sclerosis (MS). BioMS ...
... , , , , ... stem cell based,technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical,team ... 36 year old Norwegian,patient in a hospital in Beijing. The ... stem cells as well as cancer daughter,cells. The amazing outcome ...
Cached Biology Technology:Danaher Offers to Acquire Genetix Group plc for GBP 50 million pounds Sterling (USD $82 million) 2BioMS Medical provides corporate update 2BioMS Medical provides corporate update 3For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 2For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 3For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 4
(Date:4/20/2015)... DUBAI , April 20, 2015 ... soars   Glenbeigh Records Management (GRM), ... contract with Dubai Islamic Bank. Having built up an impressive ... is now a leading player within the records management sector ... company expects to double is GCC staffbase and employ a ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... office on the Texas A&M University campus, Dr. Marty Dickman,s ... pursuit of scientific excellence that,s what,s fun," Dickman said. ... is to understand what the problems are, how things work ... Dickman paused briefly and with gratitude recently to reflect on ...
... Ten researchers at the University of California, Riverside have ... of Science ( AAAS ). Including this year,s fellows, the ... with AAAS Fellow distinction is 190. Election as a ... peers. This year AAAS gave this honor to 503 of ...
... Iowa State University two of them are also affiliated ... been named fellows of the American Association for the Advancement ... their award citations are: Srinivas ... of Computer Engineering, "For distinguished contributions to high performance computational ...
Cached Biology News:Marty Dickman named AAAS Fellow 210 UC Riverside researchers recognized by the American Association for the Advancement of Science 210 UC Riverside researchers recognized by the American Association for the Advancement of Science 3AAAS honors Iowa State, Ames Lab researchers for distinguished science 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
...
Antibody Diluent for IHC 125 ml...
Biology Products: